Meet MCMi -- Faces Behind the Initiative

FDA's Medical Countermeasures initiative (MCMi) is an agency-wide effort to facilitate the availability of the drugs, vaccines, detection devices, and other equipment that will be needed to counter a chemical, biological, radioactive, or nuclear agent or an emerging infectious disease threat.  Scientific staff from FDA's three medical product centers are working on the MCMi.  And the Office of Counterterrorism and Emerging Threats (OCET) in the Office of the Commissioner is providing additional staff and resources to support their work. We invite you to meet some of the FDA staff involved in the MCMi.  

". . . the staff working on this broad agency effort are exceptionally qualified and extremely committed. This initiative is a very complex, long-term effort that calls for collaboration, continuing support, and the ability do things a little differently."

-- Luciana Borio, M.D., Assistant Commissioner for Counterterrorism Policy and Director, OCET

Luciana Borio, Director, Office of Counterterrorism and Emerging Threats

Sally Hojvat, Director of the Division of Microbiology Devices, Office of In-vitro Diagnostic (IVD) Device Evaluation and Safety,Center for Devices and Radiological Health